Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 53 Ovarian Neoplasms 4 Prostatic Neoplasms 3 Neoplasms 3 Inflammatory Breast Neoplasms 3 HER2-positive Breast Cancer 3 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Solid Tumor 2 Rectal Neoplasms 2 Neoplasm Metastasis 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Cancers 1 Patient Preference 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Her2-Positive Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-Positive Early Breast Cancer 1 HER2 Positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1

Interventions

Paclitaxel 6 Carboplatin 6 Gemcitabine 3 pembrolizumab 2 Irinotecan 2 Erlotinib Hydrochloride 2 Capecitabine 2 Bevacizumab 2 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 erythromycin propionate-N-acetylcysteinate 1 entrectinib 1 cobimetinib 1 belinostat 1 atezolizumab 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1 Vemurafenib 1 Surveys and Questionnaires 1 Oxaliplatin 1 HhAntag691 1 Everolimus 1 Etoposide 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neoplasms, Unknown Primary × pertuzumab × Clear all

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡